Diquat poisoning
Conditions
Interventions
Amantadine treatment group:Apart from conventional treatments such as blood purification, antioxidant therapy, glucocorticoid therapy, and neurological support therapy, after the patients with dicamba
Control group:NA
Sponsors
The First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
14 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age between 14 and 75 years. 2.Diagnosis consistent with the established clinical criteria for diquat poisoning. 3.Time from onset of poisoning to hospital admission = 60 mL/min/1.73 m^2, to exclude moderate-to-severe renal dysfunction. Cardiac function: Left ventricular ejection fraction (LVEF) >= 50% (indicating preserved ejection fraction and no evidence of significant heart failure) and no clinical signs of moderate-to-severe heart failure (New York Heart Association [NYHA] Class III–IV).
Exclusion criteria
Exclusion criteria: 1. Related to the subjects: Age less than 14 years old or greater than 75 years old; Patients exposed to other toxins simultaneously; Those with severe cognitive impairment or mental disorders who cannot understand the research content or are unable to provide informed consent; Pregnant or lactating women; Those with a history of amantadine or similar drug allergies; Those with severe comorbidities; Those with an expected survival period of no more than 48 hours. 2. Related to the lesion: More than one seizure within the previous month; Those who had a head injury or other primary central nervous system diseases in the past three months; Those with other serious complications that are not suitable for participating in the study. 3. Related to concomitant medication exclusion criteria: Those who are currently receiving or have recently received drugs that may affect the function of the central nervous system, such as antiparkinsonian drugs, antipsychotic drugs, antiepileptic drugs, etc.; Those who are using drugs that affect the metabolism of amantadine, such as CYP450 inducers or inhibitors; Those who are using other experimental drugs or participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 28-day survival state;The occurrence of toxic encephalopathy; | — |
Secondary
| Measure | Time frame |
|---|---|
| GCS score;SOFA score;GOS/GOSE score;CRS-R score;mBarthel ;MoCA;EQ-5D score; | — |
Countries
China
Contacts
Public ContactYuanqiang Lu
The First Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed